TECH Stock Analysis
NMS · Healthcare · Biotechnology
$72.61
+0.00 (+0.01%)
TECH Interactive Price Chart & Trading Signals
TECH Stock Snapshot — Valuation, Risk & Technical Signals
TECH Key Fundamentals, Analyst Targets & Company Profile
Key Financial Ratios
Market Cap
$11.39B
P/E Ratio
62.60
Forward P/E
31.49
PEG Ratio
2.11
P/B Ratio
5.38
EPS
$1.16
Dividend Yield
0.44%
52W Range
$43.20 – $72.69
Beta
1.27
Volume
0.5M
ROE
9.0%
Profit Margin
15.0%
Revenue Growth
1.3%
Gross Margin
66.2%
EV/EBITDA
34.15
Analyst Target
$70.73
The trailing price-to-earnings ratio stands at 62.6x. Forward P/E of 31.5x implies earnings expansion expected. Price-to-book is 5.38x. EV/EBITDA sits at 34.15x. Market capitalization is $11.39B. Revenue is growing at 1.3% on a trailing basis. Profit margins are 15.0%. Return on equity is 9.0%. Beta of 1.27 indicates elevated market sensitivity.
Analyst Consensus
Recommendation
none
Low Target
$50.00
Mean Target
$70.73
High Target
$73.00
Based on 11 analysts
About TECH
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. It operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. Its Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
TECH Deep Dive Analysis
Bottom Line
Verdict
OvervaluedBest for
Higher-risk tolerance investorsWatch out for
Premium valuation, High volatilityNon-zero inputs
4/5Counts non-zero values for price, P/E, beta, macro risk, and revenue growth; zero may mean unavailable or be a genuine zero.
Bio-Techne Corporation (TECH) trades above our multi-model fair value estimate of $23.85 by approximately 67.2%. Trailing P/E: 62.6x. Profitability signals include profit margin of 15.0% and return on equity of 9.0%. Recent growth metrics show revenue growth of 1.3%. Risk profile: elevated market beta of 1.27. Consensus: none.
Valuation, Growth & Risk
Valuation
Overvalued
P/E 62.6x
Price is above what fundamentals suggest.
Growth
Stable
Rev 1.3%
Revenue is moving sideways.
Risk
Elevated
Beta 1.27
Expect bigger swings than the market.
Valuation Snapshot
Bio-Techne Corporation (TECH) trades above our multi-model fair value estimate of $23.85 by approximately 67.2%. The trailing price-to-earnings ratio stands at 62.6x. Forward P/E of 31.5x suggests earnings compression ahead. Price-to-sales is 9.4x. Price-to-book is 5.4x. EV/EBITDA sits at 34.2x. Market capitalization is $11.39B.
Why it matters: Paying a premium works only if the company keeps growing faster than expected.
Growth & Profitability
Revenue is growing at 1.3% on a trailing basis. Profit margins are 15.0%. Return on equity is 9.0%. Return on assets is 6.7%.
Why it matters: Stable revenue is fine, but watch for margin pressure that could limit profit growth.
Risk Profile
Beta of 1.27 indicates elevated market sensitivity. Net debt position is $23.61M.
Why it matters: A riskier stock can fall more in a downturn. Make sure your portfolio can handle the volatility.
Analyst Context
Analyst consensus target of $70.73 implies 2.6% downside. Target range spans $50.00 to $73.00. 11 analysts cover the stock. Consensus recommendation: none.
Why it matters: Analyst targets reflect what professionals expect over 12 months. A wide gap between price and target can mean the market disagrees with the consensus.
Data Methodology & Sources
Market Data (Facts)
- Price, volume, and market cap: Yahoo Finance (may be delayed)
- P/E, EPS, revenue, and debt: Yahoo Finance fundamentals
- Analyst estimates: Yahoo Finance (coverage and update times vary)
- Insider transactions: Yahoo Finance (reporting may be delayed)
QuantSoar Model (Derived)
- Fair value: available outputs from seven models; outliers are filtered using MAD (k=3.5), then combined with fixed model weights.
- Margin of Safety = (Fair Value − Displayed Price) / Displayed Price × 100
- Composite Score: 40% Value + 30% Momentum + 30% Risk
- Verdict Gauge: Base 50 + Valuation (up to ±25) + Whale sentiment (up to ±10) + Insider buying (+5) + Macro risk (up to ±10) + Technical signal (up to ±10). Analyst consensus is separate.
Model outputs are estimates based on available data and are not investment advice. Cross-check with primary sources before making investment decisions.
TECH Overvalued
Bio-Techne Corporation (TECH) trades above our multi-model fair value estimate of $23.85 by approximately 67.2%.
Frequently Asked Questions
ValuationIs TECH stock overvalued right now?
ValuationWhat is TECH fair value based on current fundamentals?
RiskHow risky is TECH compared with other stocks?
GrowthIs TECH still growing?
AnalystWhat do analysts think about TECH?
DividendDoes TECH pay a dividend?
CatalystWhat could change the investment case for TECH?
Related Stocks
About the Author
Phasakorn Traklang (Peach) — Founder
Phasakorn Traklang (Peach) is the founder of QuantSoar, bringing expertise in SEO, web development, and technical analytics to build an AI-powered investment platform accessible to retail investors worldwide.
Connect on LinkedInInvestment Disclaimer: Tax treatment can depend on tax residence, account type, and tax year. This information is general and is not personal tax or investment advice. SEC
Data: Yahoo Finance / SEC EDGAR / Alpha Vantage / Finnhub. AI outputs verified against source data.